<DOC>
	<DOCNO>NCT03090269</DOCNO>
	<brief_summary>This phase II pilot study aim evaluate benefit risk methylphenidate ( ConcertaÂ® ) treatment cocaine/crack dependence term cocaine/crack use reduction adverse event .</brief_summary>
	<brief_title>Methylphenidate Cocaine Dependence</brief_title>
	<detailed_description>Patients receive pharmacotherapy base methylphenidate ( 18 mg per tablet ) 3-week titration phase maximum dose 108 mg per day , weekly follow-up 3 month . Socio-demographic behavioral data collect phone interview every month . During medical visit , self-administered clinical questionnaire collect clinical behavioral data . Urine drug toxicology blood sample perform gather biological , pharmacokinetic pharmacodynamic data . This study identify effective response-dose methylphenidate people cocaine use disorder . The methylphenidate effective reduce cocaine use cocaine-dependent individual good tolerability . The result pharmacokinetic pharmacodynamic analysis give u effective dose methylphenidate information toxicity adapt surveillance future clinical trial .</detailed_description>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>Diagnosed cocaine/crack/amphetamine derivate dependence use Diagnostic Statistical Manual Mental Disorders ( DSM V ) ( International Classification Diseases ( ICD 10 ) ) willing abstinent . Having cocaine/crack positive urinary test . Effective contraception woman childbearing age . Willing participate . Registered social insurance/security . Being able give consent . Reachable telephone . Dependence alcohol and/or substance . Hypersensitivity active compound methylphenidate filler . Glaucoma . Phaeochromocytoma Family history diagnosis Gilles de la Tourette syndrome . During treatment nonselective , irreversible monoamine oxidase ( MAO ) inhibitor . History hyperthyroidism thyrotoxicosis . Preexisting cardiovascular problem include severe hypertension , heart failure , arterial occlusive disease , angina , haemodynamically significant congenital heart disease , cardiomyopathy , myocardial infarction , potentially lifethreatening arrythmias channelopathies , ( disorder cause dysfunction ionic channel ) . Preexisting cerebrovascular disorder , cerebral aneurism , vascular abnormality include vasculitis stroke . Diagnosis history severe depression , anorexia nervosa/anorexic disorder , suicidal tendency , psychotic symptom , severe mood disorder , mania , schizophrenia , psychopathic/borderline personality disorder Diagnosis history severe episodic ( Type I ) Bipolar ( affective ) Disorder ( wellcontrolled ) Suicidal tendencies characterize suicidal syndrome . Pregnancy , breastfeed absence contraception female participant . Unstabilized psychiatric comorbidity likely compromise adherence treatment . Comorbidity handicap likely corrupt evaluation . Organic pathology severe enough accord investigator , likely comprise adequate surveillance trial . Patient leave area period time prevent his/her adequate participation trial . Insufficient motivation . Participation another clinical trial ongoing exclusion period time preinclusion visit . Lack medical insurance . Unreachable phone . Patient mandatory treatment . Patient legal incapacity ( guardianship curatorship )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>cocaine</keyword>
	<keyword>methylphenidate</keyword>
	<keyword>psychostimulant</keyword>
	<keyword>ADHD</keyword>
	<keyword>effective dose</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>crack</keyword>
</DOC>